<DOC>
	<DOCNO>NCT00987974</DOCNO>
	<brief_summary>Rationale : Apart cholesterol lower effect , statin cholesterol‐independent pleiotropic action , upregulation 5'‐ectonucleotidase up‐regulation NO‐synthase may increase tolerance ischemia‐reperfusion injury ( IR‐injury ) . Several animal study show reduction IR‐injury result statin treatment heart kidney . Recently investigator show , use Annexin A5 target voluntary ischemic exercise ass IR‐injury , protective effect 7 day oral rosuvastatin treatment . A three day treatment atorvastatin however fail reduce annexin target . Assessment flow mediate dilation brachial artery measure endothelial ( dy ) function , validate model research effect possible protective strategy perform mechanistic experiment IR‐injury human vivo . The investigator hypothesize pretreatment statin increase endothelial tolerance ischemia reperfusion injury . Objective : To study protective effect pretreatment ( 3 day 7 day ) rosuvastatin atorvastatin flow mediate dilation 15 minute ischemia 15 minute reperfusion . Study design : placebo‐controlled randomise double‐blind trial Study population : Healthy volunteer , age 18‐50 Intervention : Treatment either rosuvastatin 20 mg , atorvastatin 80mg placebo either 3 7 day Main study parameter : Difference flow mediate dilation 15 minute ischemia . Nature extent burden risk associate participation , benefit group relatedness : Treatment rosuvastatin atorvastatin expect harm volunteer . Most reported side effect rosuvastatin atorvastatin gastro‐intestinal complains myalgia . The volunteer benefit directly participate study .</brief_summary>
	<brief_title>Short Term Statin Treatment Endothelial Dysfunction Due Ischemia Reperfusion Injury</brief_title>
	<detailed_description />
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Reperfusion Injury</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Age 18‐50 Written inform consent Smoking History cardiovascular disease Hypertension ( supine position : systole &gt; 140 mmHg , diastole &gt; 90 mmHg ) Diabetes Mellitus ( fast glucose &gt; 7.0 mmol/L random glucose &gt; 11.0 mmol/L ) Hyperlipidaemia ( fast total cholesterol &gt; 5.5 mmol/L random cholesterol &gt; 6.5 mmol/L ) Alanine amino transferase &gt; 90 U/L Creatine kinase &gt; 440 U/L Raised rhabdomyolysis risk GFR &lt; 60 ml/min Overt clinical sign hypothyroidism Myopathy family history Alcohol abuse Concomitant chronic use medication Participation drug‐investigation previous 60 day check VIP check . Professional athlete</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2001</verification_date>
	<keyword>ischemia reperfusion injury</keyword>
	<keyword>endothelial dysfunction</keyword>
	<keyword>statin</keyword>
	<keyword>rosuvastatin</keyword>
	<keyword>atorvastatin</keyword>
	<keyword>placebo</keyword>
	<keyword>ecto-5'-nucleotidase</keyword>
	<keyword>flow mediate dilation</keyword>
</DOC>